117 related articles for article (PubMed ID: 32827690)
1. Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells.
Natarajan U; Venkatesan T; Dhandayuthapani S; Dondapatti P; Rathinavelu A
Cell Signal; 2020 Nov; 75():109742. PubMed ID: 32827690
[TBL] [Abstract][Full Text] [Related]
2. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation.
Jiang M; Pabla N; Murphy RF; Yang T; Yin XM; Degenhardt K; White E; Dong Z
J Biol Chem; 2007 Jan; 282(4):2636-45. PubMed ID: 17130128
[TBL] [Abstract][Full Text] [Related]
3. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Jin L; Tabe Y; Kojima K; Zhou Y; Pittaluga S; Konopleva M; Miida T; Raffeld M
Cancer Lett; 2010 Dec; 299(2):161-70. PubMed ID: 20850924
[TBL] [Abstract][Full Text] [Related]
4. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins.
Wang XH; Zhang SF; Bao JT; Liu FY
Tumour Biol; 2017 Jun; 39(6):1010428317701638. PubMed ID: 28618955
[TBL] [Abstract][Full Text] [Related]
5. Wilms' tumor gene 1 enhances nutlin-3-induced apoptosis.
Lee SY; Choe YJ; Park JY; Lee SS; Kim YH; Shin SJ; Chung YJ; Kim HS
Oncol Rep; 2014 Jan; 31(1):131-6. PubMed ID: 24190574
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
Aziz MH; Shen H; Maki CG
Oncogene; 2011 Nov; 30(46):4678-86. PubMed ID: 21643018
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
8. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.
Vaseva AV; Marchenko ND; Moll UM
Cell Cycle; 2009 Jun; 8(11):1711-9. PubMed ID: 19411846
[TBL] [Abstract][Full Text] [Related]
9. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
[TBL] [Abstract][Full Text] [Related]
10. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
11. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
13. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Liu Q; Mier JW; Panka DJ
Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
[TBL] [Abstract][Full Text] [Related]
14. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
[TBL] [Abstract][Full Text] [Related]
15. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.
Davaadelger B; Perez RE; Zhou Y; Duan L; Gitelis S; Maki CG
Cancer Biol Ther; 2017 Nov; 18(11):895-903. PubMed ID: 28696156
[TBL] [Abstract][Full Text] [Related]
16. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
17. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM; Bhattacharya S; Johnson LR
Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1
Kanagasabai T; Venkatesan T; Natarajan U; Alobid S; Alhazzani K; Algahtani M; Rathinavelu A
Cell Signal; 2020 Feb; 66():109435. PubMed ID: 31706019
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
20. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]